Capricor's DMD Therapy Shows Major Promise in Phase 3 Trial

Capricor's (CAPR) deramiocel cell therapy achieved significant skeletal and cardiac improvements in Duchenne muscular dystrophy patients, potentially reversing FDA rejection after July setback.